MGF (MECHANO GROWTH FACTOR) - Research Grade Peptide

MGF (MECHANO GROWTH FACTOR) – Research-Grade 24-Residue E-Domain Peptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade synthetic MGF E-domain peptide with batch documentation available where supplied
• Defined peptide corresponding to the 24-residue C-terminal E-domain sequence associated with human IGF-1Ec
• Non-PEGylated peptide presentation unless expressly stated otherwise in the applicable batch documentation
• Supplied as lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, amino-acid sequence, terminal form, chromatographic purity, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

All of our research peptides and related laboratory materials are supplied strictly for scientific research and laboratory use only. Each vial contains lyophilised material prepared to support controlled laboratory handling and storage. The stated nominal amount refers to the declared MGF peptide content of a single vial, subject to the applicable batch documentation. Where dissolution or reconstitution is required, the solvent, buffer, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: MGF (MECHANO GROWTH FACTOR)
• Preferred Product Description: Synthetic human MGF 24-residue E-domain research peptide
• Alternative Names: MGF; Mechano Growth Factor; MGF E-domain peptide; MGF-24aa-E peptide; human IGF-1Ec E-domain peptide
• Material Classification: Synthetic linear 24-residue peptide
• Sequence Length: 24 amino-acid residues
• Reference Human Sequence: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys
• One-Letter Reference Sequence: YQPPSTNKNTKSQRRKGSTFEEHK
• Sequence Origin: Corresponds to the distinctive C-terminal E-domain sequence associated with the human IGF-1Ec splice variant
• N-Terminal Structure: Free tyrosine amino terminus unless otherwise stated in the applicable batch documentation
• C-Terminal Structure: Batch-specific; the applicable Certificate of Analysis must identify whether the terminal lysine is supplied as a free carboxylic acid or C-terminal amide
• Reference Free-Acid Sequence: H-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys-OH
• Calculated Free-Acid Molecular Formula: C₁₂₁H₁₉₄N₄₀O₄₀
• Calculated Free-Acid Average Molecular Weight: Approximately 2849.08 g/mol
• Reference C-Terminal Amide Sequence: H-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys-NH₂
• Calculated C-Terminal Amide Molecular Formula: C₁₂₁H₁₉₅N₄₁O₃₉
• Calculated C-Terminal Amide Average Molecular Weight: Approximately 2848.09 g/mol
• MGF Reference Substance UNII: Q86M4KXC2P
• C-Terminally Amidated MGF Reference Substance UNII: Y65LH7J9BL
• CAS Number: The exact CAS number should be confirmed against the complete sequence, stereochemistry and terminal structure of the material supplied; CAS number 87616-84-0 is not applicable to MGF
• PEG Status: This listing describes non-PEGylated MGF unless PEG conjugation, PEG molecular weight, conjugation site and polydispersity are expressly stated in the applicable batch documentation
• Full-Length IGF-1Ec Distinction: The isolated 24-residue MGF E-domain peptide is not chemically identical to the larger full-length IGF-1Ec precursor or propeptide
• Sequence-Variant Control: Alternative MGF-related research constructs may contain an arginine rather than histidine near the C-terminus, D-arginine substitutions, terminal amidation or other stabilising modifications
• Stereochemical Confirmation: Mass spectrometry alone does not normally distinguish L-arginine from D-arginine residues; any D-amino-acid substitutions should therefore be supported by synthesis records or suitable stereochemical analysis
• Physical Form: Lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Peptide-Content Specification: Net MGF peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion, residual-solvent and formulation results
• Nominal Amount Basis: The product specification should state whether the declared vial amount is expressed as net MGF peptide, total salt-form material or total formulated lyophilised material
• Counter-Ion Confirmation: Acetate, trifluoroacetate or another counter-ion may affect the total material mass, calculated molecular weight and net peptide content of the supplied laboratory material
• Sequence Confirmation: The complete 24-residue amino-acid sequence should be confirmed using the applicable synthesis and batch records
• Terminal-Structure Confirmation: Molecular-identity documentation should establish whether the C-terminal lysine is present as the free acid or amide
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the exact sequence and terminal form stated for the applicable batch
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely deprotected material, oxidation products, stereochemical impurities and other synthesis-related or process-related impurities are separate quality attributes
• Endotoxin Specification: The applicable bacterial endotoxin or LPS result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Analytical Interpretation: Molecular identity, amino-acid sequence, stereochemistry, terminal structure, chromatographic purity, net peptide content, aggregation, water content, residual solvent content, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for review.
✓ Certificate of Analysis – Accessible through the product QR code where provided for the applicable batch.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete 24-residue amino-acid sequence should be confirmed using the applicable batch and synthesis records.
✓ Terminal-structure documentation – The free-acid or C-terminal amide form should be identified clearly in the applicable batch documentation.
✓ Stereochemical documentation – Any D-amino-acid substitutions should be declared and supported by appropriate production or analytical records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the stated MGF construct.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net MGF peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ PEG-status documentation – The material should be identified expressly as non-PEGylated or PEGylated, with the PEG specification stated where applicable.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or LPS result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

MGF Product Overview

Our MGF research-grade 24-residue E-domain peptide is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows and reference-material comparison. The product is intended to represent the distinctive C-terminal E-domain sequence associated with the human IGF-1Ec splice variant.

The term MGF is used inconsistently across scientific literature and commercial catalogues. It may describe the IGF-1Ec transcript, a larger precursor protein, a synthetic 24-residue E-domain peptide, a C-terminally amidated analogue, a stereochemically modified research peptide or a PEGylated derivative. This PEP039 listing is intended specifically for the non-PEGylated 24-residue peptide construct identified in the applicable batch documentation.

Product identity, amino-acid sequence, stereochemical configuration, terminal structure, chromatographic purity, net peptide content, molecular form, counter-ion content, water content, residual solvents, aggregation, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis. Chromatographic purity should not automatically be interpreted as equivalent to the total net peptide content of the vial.

The reference human sequence YQPPSTNKNTKSQRRKGSTFEEHK has a calculated molecular weight of approximately 2849.08 g/mol when represented with free amino and carboxylic acid termini. The corresponding C-terminal amide has a calculated molecular weight of approximately 2848.09 g/mol. The applicable PEP039 Certificate of Analysis should identify which terminal form is actually supplied.

The MGF research peptide described here is not GHRP-6, is not full-length IGF-1Ec and is not PEG-MGF. Those materials have different molecular structures, analytical masses and product specifications and should be maintained as separate catalogue identities.

For the majority of routine analytical, chromatographic, peptide-characterisation and general laboratory work, the Regular MGF specification remains highly suitable. The premium black-and-gold ULTIMATE MGF option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet